Niagen Bioscience (NASDAQ: NAGE) investors back board, pay and auditor
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Niagen Bioscience, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders elected all eight director nominees, including Frank L. Jaksch, Jr., Robert Fried, Steven Rubin, Wendy Yu, Gary Ng, Kristin Patrick, Ann Cohen, and Hamed Shahbazi.
Stockholders also ratified the appointment of Crowe LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 56,152,066 votes for and 2,256,090 against. In addition, they approved, on an advisory basis, the compensation of the company’s named executive officers.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Votes for Frank L. Jaksch, Jr.: 44,531,507 For
Votes for Robert Fried: 44,822,825 For
Auditor ratification For votes: 56,152,066 For
+3 more
6 metrics
Votes for Frank L. Jaksch, Jr.
44,531,507 For
Election as director at 2026 Annual Meeting
Votes for Robert Fried
44,822,825 For
Election as director at 2026 Annual Meeting
Auditor ratification For votes
56,152,066 For
Ratification of Crowe LLP for fiscal year ending December 31, 2026
Auditor ratification Against votes
2,256,090 Against
Proposal 2 at 2026 Annual Meeting
Say-on-pay For votes
43,188,958 For
Advisory vote on named executive officer compensation
Broker non-votes on director items
13,274,979 broker non-votes
Each director election and say-on-pay proposal
Key Terms
broker non-votes, independent registered public accounting firm, on an advisory basis, emerging growth company, +1 more
5 terms
broker non-votes financial
"No broker non-votes arose in connection with Proposal 2."
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"Ratification of the appointment of Crowe LLP as the Company's independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
on an advisory basis financial
"Approval, on an advisory basis, of the compensation paid to the Company’s named executive officers."
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
named executive officers financial
"compensation paid to the Company’s named executive officers."
Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.
FAQ
What did Niagen Bioscience (NAGE) stockholders decide about the board of directors?
Niagen Bioscience stockholders elected all eight director nominees to serve until the 2027 Annual Meeting. Each nominee, including Frank L. Jaksch, Jr. and Robert Fried, received more "For" than "Withheld" votes, with additional broker non-votes reported for each director.
Did Niagen Bioscience (NAGE) stockholders ratify the company’s independent auditor?
Yes, stockholders ratified Crowe LLP as Niagen Bioscience’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote was 56,152,066 "For," 2,256,090 "Against," and 158,200 "Abstain," with no broker non-votes on this proposal.
How did Niagen Bioscience (NAGE) investors vote on executive compensation?
Stockholders approved, on an advisory basis, the compensation of Niagen Bioscience’s named executive officers. Proposal 3 received 43,188,958 votes "For," 1,930,441 "Against," 171,978 "Abstain," and 13,274,979 broker non-votes, indicating overall support for the current pay structure.
What were the broker non-votes at Niagen Bioscience’s 2026 Annual Meeting?
For the director elections and the advisory vote on executive compensation, Niagen Bioscience reported 13,274,979 broker non-votes. For the auditor ratification proposal, the company noted that no broker non-votes arose, reflecting typical discretionary voting by brokers on that item.
Which accounting firm will audit Niagen Bioscience (NAGE) for fiscal 2026?
Crowe LLP will serve as Niagen Bioscience’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Stockholders ratified this appointment at the 2026 Annual Meeting through Proposal 2, which received strong support in the shareholder vote results.